




<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449				ATTY. DOCKET NO. A-65358/RFT/DAV		SERIAL NO 08/908,469			
				APPLICANT: BACA et al.					
				FILING DATE August 6, 1997		GROUP 1642			
<b>U.S. PATENT DOCUMENTS</b>									
EXAMINER'S INITIALS		PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE		
LAP	A	5,580,723	12/1996	Wells et al.	—	—			
<b>FOREIGN PATENT DOCUMENTS</b>									
EXAMINER'S INITIALS		PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation		
							Yes	No	
LAP	B	92/22653 ✓	12/1992	WO	—	—			
LAP	C	2 268 744 ✓	1/1994	GB	—	—			
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>									
LAP	1/	Bending, M.M. "Humanization of Rodent Monoclonal Antibodies," <i>Methods: A Companion to Methods In Enzymology</i> 8:83-93 (1994).							
LAP	2/	Baca et al., "Antibody Humanization Using Monovalent Phage Display," <i>Journal of Biological Chemistry</i> 272(16):10678-10684 (1997).							
LAP	3/	Garrard et al., "Assembly and Enrichment in a Monovalent Phage Display System," <i>Biotechnology</i> , 9:1373-1377 (1991).							
LAP	4/	Chang et al., "High-level secretion of human growth hormone by <i>Escherichia coli</i> ," <i>Gene</i> , 55:189-196 (1987).							
LAP	5/	Kunkel et al., "Efficient Site-Directed Mutagenesis Using Uracil-Containing DNA," <i>Methods Enzymol.</i> , 204:125-139 (1991).							
LAP	6/	Winter et al., "Making Antibodies by Phage Display Technology," <i>Ann. Rev. Immunol.</i> , 12:433-455 (1994).							
LAP	7/	Vieira et al., "Production of Single-Stranded Plasmid DNA," <i>Methods Enzymol.</i> , 153:3-11 (1987).							
LAP	8/	Karlsson et al., "Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system," <i>J. Immun. Methods</i> , 145:229-240 (1991).							
LAP	9/	Cunningham et al., "Production of an atrial natriuretic peptide variant that is specific for type A receptor," <i>EMBO J.</i> 13(11):2508-2515 (1994).							
EXAMINER				DATE CONSIDERED					
				10/31/01					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 8085 1449A.FRM (8/95)

# INFORMATION DISCLOSURE CITATION

PTO-1449

ATTY. DOCKET NO.  
A-65358/RFT/DAVSERIAL NO.  
09/908,468APPLICANT:  
BACA et al.FILING DATE  
April 6, 1997GROUP  
1642

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

WPA	10	Folkman et al., "Angiogenesis," <i>J. Biol. Chem.</i> , 267(16):10931-10934 (1992).
WPA	11	Klagsbrun et al., "Regulators of Angiogenesis," <i>Annu. Rev. Physiol.</i> , 53:217-239 (1991).
WPA	12	Garner, A., "Vascular Diseases", <i>Pathobiology of Ocular Disease. A Dynamic Approach</i> . 2nd Ed. (Garner and Klintworth, eds.) Marcel Dekker:New York, pp. 1625-1710 (1994).
WPA	13	Weidner et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," <i>New Engl. J. Med.</i> , 324(1):1-8 (1991).
WPA	14	Horak et al., "Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer," <i>Lancet</i> , 340:1120-1124 (1992).
WPA	15	Macchiarini et al., "Relation of neovascularisation to metastasis of non-small-cell lung cancer," <i>Lancet</i> , 340:145-146 (1992).
WPA	16	Good et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin," <i>Proc. Natl. Acad. Sci. USA</i> , 87:6624-6628 (1990).
WPA	17	Clapp et al., "The 16-Kilodalton N-Terminal Fragment of Human Prolactin is a Potent Inhibitor of Angiogenesis," <i>Endocrinology</i> , 133(3):1292-1299 (1993).
WPA	18	O'Reilly et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," <i>Cell</i> , 79:315-328 (1994).
WPA	19	O'Reilly et al., "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," <i>Cell</i> , 88:277-285 (1997).
WPA	20	Ferrara et al., "The Biology of Vascular Endothelial Growth Factor," <i>Endocr. Rev.</i> , 18(1):4-25 (1997).
WPA	21	Berkman et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms," <i>J. Clin. Invest.</i> , 91:153-159 (1993).
WPA	22	Brown et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Breast Cancer," <i>Human Pathol.</i> , 26(1):86-91 (1995).
WPA	23	Brown et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract," <i>Cancer Res.</i> , 53:4727-4735 (1993).
WPA	24	Mattern et al., "Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma," <i>Brit. J. Cancer</i> , 73:931-934 (1996).
WPA	25	Dvorak et al., "Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis," <i>Am. J. Pathol.</i> , 146(5):1029-1039 (1995).
WPA	26	Aiello et al., "Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinal Disorders," <i>New Engl. J. Med.</i> , 331:1480-1487 (1994).
WPA	27	Lopez et al., "Transdifferentiated Retinal Pigment Epithelial Cells Are Immunoreactive for Vascular Endothelial Growth Factor in Surgically Excised Age-Related Macular Degeneration-Related Choroidal Neovascular Membranes," <i>Invest. Ophthol. Vis. Sci.</i> , 37(5):855-868 (1996).
WPA	28	Warren et al., "Regulation by Vascular Endothelial Growth Factor of Human Color Cancer Tumorigenesis in a Mouse Model of Experimental Liver Metastasis," <i>J. Clin. Invest.</i> , 95:1789-1797 (1995).

EXAMINER

DATE CONSIDERED


10/31/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 8085 1449A.FRM (8/95)

<b>INFORMATION DISCLOSURE CITATION</b>  PTO-1449		ATTY. DOCKET NO. A-65358-1/RFT/DAV	SERIAL NO. 09/908,489
		APPLICANT: BACA et al.	
		FILING DATE April 6, 1997	GROUP 1642

O I P  
 OCT 14 1999  
 PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
LMA	29	Borgström et al., "Complete Inhibition of Angiogenesis and Growth of Microtumors by Anti-Vascular Endothelial Growth Factor Neutralizing Antibody: Novel Concepts of Angiostatic Therapy from Intravital Videomicroscopy," <i>Cancer Res.</i> , 56:4032-4039 (1996).
LMA	30	Melnyk et al., "Vascular Endothelial Growth Factor Promotes Tumor Dissemination by a Mechanism Distinct from Its Effect on Primary Tumor Growth," <i>Cancer Res.</i> , 56:921-924 (1996).
LMA	31	Adamis et al., "Prohibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascularization in a Nonhuman Primate," <i>Arch. Ophthalmol.</i> , 114:66-71 (1996).
LMA	32	DeVries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <i>Science</i> , 255:989-991 (1992).
LMA	33	Leung et al., "Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen," <i>Science</i> , 246:1306-1309 (1989).
LMA	34	Sanger et al., "DNA sequencing with chain-terminating inhibitors," <i>Proc. Natl. Acad. Sci. USA</i> , 74(12):5463-5467 (1977).
LMA	35	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," <i>J. Gen. Virol.</i> , 36:59-72 (1977).
LMA	36	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1," <i>J. Immunol.</i> , 157:4986-4995 (1996).
LMA	37	Eigenbrot et al., "X-ray Structures of the Antigen-binding Domains from Three Variants of Humanized anti-p185 <sup>HER2</sup> ," <i>J. Mol. Biol.</i> , 229:969-995 (1993).
LMA	38	Kunkel et al., "Rapid and efficient site-specific mutagenesis without phenotypic selection," <i>Proc. Natl. Acad. Sci. USA</i> , 82:488-492 (1985).
LMA	39	Eaton et al., "Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule," <i>Biochemistry</i> , 25(26):8343-8347 (1986).
LMA	40	Gorman et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line," <i>DNA Prot. Eng. Tech.</i> , 2:3-10 (1990).
LMA	41	Lucas et al., "High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector," <i>Nucleic Acid Res.</i> , 24(9):1774-1779 (1996).
LMA	42	Chisholm, "High Efficiency Gene Transfer into Mammalian Cells," <i>DNA Cloning 4. Mammalian Systems</i> , Glover, D.M., Hames, B.D. eds., Oxford University Press, Oxford, pp. 1-41 (1995).
LMA	43	Park et al., "Placenta Growth Factor," <i>J. Biol. Chem.</i> , 269(41):25646-25654 (1994).
LMA	44	Karlsson et al., "Kinetic and Concentration Analysis Using BIA Technology," <i>Methods: A Comparison to Methods in Enzymology</i> , 6:99-110 (1994).
LMA	45	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties," <i>Proteins</i> , 8:309-314 (1990).
LMA	46	Lowman et al., "Selecting High-Affinity Binding Proteins by Monovalent Phage Display," <i>Biochemistry</i> , 30:10832-10838 (1991).

EXAMINER	DATE CONSIDERED
	10/31/01